Scemblix (Asciminib Hydrochloride) Patent Expiration, LOE Window & CMS Spending
Scemblix (Asciminib Hydrochloride) by Novartis: FDA Orange Book core substance LOE 2040-05-14 (last listed 2040-05-17), 0 AB generics, $257.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N215358 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-05-14 |
| Last Listed Patent or Exclusivity Date | 2040-05-17 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $257.3M |
| 2024 Medicare Part D Spend | $197.2M |
| 2024 Medicaid Spend | $60.1M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 21.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.